Clinical Trial Update: Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating ALLN-177 in patients with enteric hyperoxaluria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enteric Hyperoxaluria

Drugs mentioned

• ALLN-177

Snippet

Sponsor: Allena Pharmaceuticals | Conditions: Enteric Hyperoxaluria | Phase 3 | Status: COMPLETED